Roman Hájek

55PUBLICATIONS
356CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Regenerative medicine (incl. stem cells)Medical bacteriologyMedical mycology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (55)

|Jun 12, 2026
Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma.

|Feb 27, 2026
Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma: dynamics of MRD negativity in the IMROZ study.

Robert Z Orlowski, Meletios A Dimopoulos, Xavier Leleu

|Feb 24, 2026
Early mortality with bispecific antibody therapy in RRMM: an IMWG immunotherapy database real-world analysis.

Carlyn Rose Tan, Saad Z Usmani, Andriy Derkach

|Dec 27, 2025
Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCO.

Gurdeep Parmar, Marcelo Capra, Fernanda Seguro

|Dec 17, 2025
Selective B-cell subset depletion underlies increased infection risk in patients with MM treated with anti-BCMA vs anti-GPRC5D bsAbs.

Tomas Jelinek, David Zihala, Aintzane Zabaleta

|Nov 14, 2025
Composition and Functional State of T and NK Cells in the Extramedullary Myeloma Tumor Microenvironment.

Anjana Anilkumar Sithara, Veronika Kapustova, David Zihala

Pageof 10

Frequent Collaborators

14 joint publications

Tomas Jelinek

8 joint publications

Meletios-Athanasios Dimopoulos

7 joint publications

Tereza Popkova

6 joint publications

Sabina Sevcikova